FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3170316855> ?p ?o ?g. }

• W3170316855 endingPage "e19532" @default.
• W3170316855 startingPage "e19532" @default.
• W3170316855 abstract "e19532 Background: Follicular lymphoma (FL) is a common type of non-Hodgkin’s lymphoma with high rates of recurrence. The conventional therapy for R/R FL is not curative. Duvelisib is a potent inhibitor of both PI3K-δ and PI3K-γ that has been approved by the FDA for pts with R/R chronic lymphocytic leukemia, R/R small lymphocytic lymphoma, and R/R FL after at least two prior therapies. The current study aimed to evaluate the efficacy and safety of duvelisib in Chinese pts with R/R FL after at least two prior therapies. The current study aimed to evaluate the efficacy and safety of duvelisib in Chinese pts with R/R FL after at least two prior therapies. Methods: This was a single-arm, open-label, multi-center, phase Ⅱ clinical trial. Adult pts (ECOG ≤ 2) with histologically confirmed FL who have progressed on or relapsed after at least two prior therapies (at least one prior therapy was rituximab-contained regimen) were recruited. The main exclusion criteria were pts with grade 3b FL or those whose condition showed a propensity to transform to aggressive lymphoma. Duvelisib 25 mg was administered orally, twice daily in a 28-day cycle (max. 12 cycles) until disease progression, intolerable toxicity, death, or withdrawal. The primary endpoint was ORR as determined by Independent Review Committee (IRC) based on the revised International Working Group response criteria for Malignant Lymphoma (IWG 2007). Secondary endpoints included ORR reported by investigators as per IWG 2007; ORR reported by IRC and investigators as per Lugano 2014 criteria; DOR; PFS; OS; TTR; and safety outcomes. Results: 23 pts (22 R/R FL and 1 diffuse large B cell lymphoma) were enrolled and included in efficacy and safety analyses (last patient first dose was on Jun 30, 2020). The median age was 49 (range, 31-70) years, and 30% were females. At the data cut-off date (Dec 30, 2020), as per IWG 2007, the ORR reported by IRC was 83%, with a best response of 6 complete responses (CR) and 13 partial responses (PR); and the ORR reported by investigators was 78%, with a best response of 18 PR. As per Lugano 2014 criteria, the ORR was 83% by IRC (7 CR + 12 PR) and 78% by investigators (2 CR + 16 PR). Median DOR, PFS, and OS have not been reached. Median TTR was 1.8 (range, 1.6-5.5) months by IRC. Treatment-related adverse events (TRAEs) of any grade occurred in 21 (91%) of 23 pts, in which 12 (52%) were ≥ grade 3. The most common ( > 20%) TRAEs were neutropenia (16, 70%), increased alanine aminotransferase (11, 48%), increased aspartate aminotransferase (10, 44%), leukopenia (7, 30%), thrombocytopenia (6, 26%), increased lactate dehydrogenase (5, 22%), and rash (5, 22%). Conclusions: Duvelisib yielded impressive anti-tumor activity with manageable safety profiles in Chinese R/R FL pts and could be a compelling treatment option in this setting. Clinical trial information: NCT04707079." @default.
• W3170316855 created "2021-06-22" @default.
• W3170316855 creator A5001104633 @default.
• W3170316855 creator A5005508816 @default.
• W3170316855 creator A5006621752 @default.
• W3170316855 creator A5029441253 @default.
• W3170316855 creator A5044475779 @default.
• W3170316855 creator A5045752884 @default.
• W3170316855 creator A5048824510 @default.
• W3170316855 creator A5052901056 @default.
• W3170316855 creator A5057855713 @default.
• W3170316855 creator A5069311189 @default.
• W3170316855 creator A5070850471 @default.
• W3170316855 creator A5071427974 @default.
• W3170316855 creator A5072923976 @default.
• W3170316855 creator A5075861470 @default.
• W3170316855 creator A5076036955 @default.
• W3170316855 creator A5083531621 @default.
• W3170316855 creator A5089823522 @default.
• W3170316855 creator A5089850088 @default.
• W3170316855 creator A5090241332 @default.
• W3170316855 creator A5091912766 @default.
• W3170316855 date "2021-05-20" @default.
• W3170316855 modified "2023-10-16" @default.
• W3170316855 title "Efficacy and safety of duvelisib, a phosphoinositide 3 kinase (PI3K) δ and γ inhibitor, in Chinese patients (pts) with relapsed/refractory follicular lymphoma (R/R FL): A single-arm, open-label, multicenter, phase Ⅱ clinical trial." @default.
• W3170316855 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.e19532" @default.
• W3170316855 hasPublicationYear "2021" @default.
• W3170316855 type Work @default.
• W3170316855 sameAs 3170316855 @default.
• W3170316855 citedByCount "2" @default.
• W3170316855 countsByYear W31703168552023 @default.
• W3170316855 crossrefType "journal-article" @default.
• W3170316855 hasAuthorship W3170316855A5001104633 @default.
• W3170316855 hasAuthorship W3170316855A5005508816 @default.
• W3170316855 hasAuthorship W3170316855A5006621752 @default.
• W3170316855 hasAuthorship W3170316855A5029441253 @default.
• W3170316855 hasAuthorship W3170316855A5044475779 @default.
• W3170316855 hasAuthorship W3170316855A5045752884 @default.
• W3170316855 hasAuthorship W3170316855A5048824510 @default.
• W3170316855 hasAuthorship W3170316855A5052901056 @default.
• W3170316855 hasAuthorship W3170316855A5057855713 @default.
• W3170316855 hasAuthorship W3170316855A5069311189 @default.
• W3170316855 hasAuthorship W3170316855A5070850471 @default.
• W3170316855 hasAuthorship W3170316855A5071427974 @default.
• W3170316855 hasAuthorship W3170316855A5072923976 @default.
• W3170316855 hasAuthorship W3170316855A5075861470 @default.
• W3170316855 hasAuthorship W3170316855A5076036955 @default.
• W3170316855 hasAuthorship W3170316855A5083531621 @default.
• W3170316855 hasAuthorship W3170316855A5089823522 @default.
• W3170316855 hasAuthorship W3170316855A5089850088 @default.
• W3170316855 hasAuthorship W3170316855A5090241332 @default.
• W3170316855 hasAuthorship W3170316855A5091912766 @default.
• W3170316855 hasConcept C126322002 @default.
• W3170316855 hasConcept C141071460 @default.
• W3170316855 hasConcept C143998085 @default.
• W3170316855 hasConcept C197934379 @default.
• W3170316855 hasConcept C203092338 @default.
• W3170316855 hasConcept C2777058707 @default.
• W3170316855 hasConcept C2777938653 @default.
• W3170316855 hasConcept C2778461978 @default.
• W3170316855 hasConcept C2779260929 @default.
• W3170316855 hasConcept C2779338263 @default.
• W3170316855 hasConcept C2779878957 @default.
• W3170316855 hasConcept C2780653079 @default.
• W3170316855 hasConcept C2781413609 @default.
• W3170316855 hasConcept C31760486 @default.
• W3170316855 hasConcept C535046627 @default.
• W3170316855 hasConcept C71924100 @default.
• W3170316855 hasConcept C90924648 @default.
• W3170316855 hasConceptScore W3170316855C126322002 @default.
• W3170316855 hasConceptScore W3170316855C141071460 @default.
• W3170316855 hasConceptScore W3170316855C143998085 @default.
• W3170316855 hasConceptScore W3170316855C197934379 @default.
• W3170316855 hasConceptScore W3170316855C203092338 @default.
• W3170316855 hasConceptScore W3170316855C2777058707 @default.
• W3170316855 hasConceptScore W3170316855C2777938653 @default.
• W3170316855 hasConceptScore W3170316855C2778461978 @default.
• W3170316855 hasConceptScore W3170316855C2779260929 @default.
• W3170316855 hasConceptScore W3170316855C2779338263 @default.
• W3170316855 hasConceptScore W3170316855C2779878957 @default.
• W3170316855 hasConceptScore W3170316855C2780653079 @default.
• W3170316855 hasConceptScore W3170316855C2781413609 @default.
• W3170316855 hasConceptScore W3170316855C31760486 @default.
• W3170316855 hasConceptScore W3170316855C535046627 @default.
• W3170316855 hasConceptScore W3170316855C71924100 @default.
• W3170316855 hasConceptScore W3170316855C90924648 @default.
• W3170316855 hasIssue "15_suppl" @default.
• W3170316855 hasLocation W31703168551 @default.
• W3170316855 hasOpenAccess W3170316855 @default.
• W3170316855 hasPrimaryLocation W31703168551 @default.
• W3170316855 hasRelatedWork W1994176969 @default.
• W3170316855 hasRelatedWork W2028043880 @default.
• W3170316855 hasRelatedWork W2062566755 @default.
• W3170316855 hasRelatedWork W2066564017 @default.
• W3170316855 hasRelatedWork W2084396664 @default.
• W3170316855 hasRelatedWork W2125229272 @default.
• W3170316855 hasRelatedWork W2414728329 @default.
• W3170316855 hasRelatedWork W2525877428 @default.

• next